EXAS250117P87500
- 31.90
- 0.000.00%
Exact Sciences Newsroom
Forecasting The Future: 19 Analyst Projections For Exact Sciences
Exact Sciences Initiated at Overweight by Barclays
Barclays Initiates Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $70
Craig-Hallum Maintains Exact Sciences(EXAS.US) With Buy Rating
Exact Sciences (EXAS) Receives a Buy From Craig-Hallum
Exact Sciences Post Positive Results From MRD Trial
Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer
Express News | Exact Sciences Plans To Present 11 Abstracts At ASCO GI Meeting In San Francisco
Exact Sciences Demonstrates Leadership in Cancer Innovation With New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
Exact Sciences Corporation (NASDAQ:EXAS) Is Expected To Breakeven In The Near Future
Exact Sciences: Strong Screening Revenue Growth and Strategic Initiatives Justify Buy Rating
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $65 to $86
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
Exact Sciences Price Target Maintained With a $65.00/Share by Benchmark
Exact Sciences Analyst Ratings
Craig-Hallum Sticks to Their Buy Rating for Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Exact Sciences (EXAS) and Exelixis (EXEL)
Exact Sciences Boosts Finances and Plans New Launches
Express News | Exact Sciences Corp - Enters Into Senior Secured Revolving Credit Agreement